TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
News|Articles|July 1, 2026
9 Endocrinology Headlines You Missed in June 2026
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.
Advertisement
Advertisement
June was a very active month for endocrinology, with major
Related to this article
Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
Stay updated with the latest healthcare breakthroughs, including 96-week durability data for GSK’s bepirovirsen in hepatitis B, and more.
In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.
Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.
HIBISCUS showed a 48.7% vs 7.2% hemoglobin response at week 24, with an FDA decision expected in 2027.
Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.
Advertisement
Advertisement